Candel Therapeutics, Inc. (CADL) Stock

Candel Therapeutics, Inc. (CADL) is a Healthcare stock trading at $8.33 (as of 2026-06-18), with a market capitalization of $608.14M and a trailing P/E of -8.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer patients. Its pipeline includes CAN-2409 across Phase II/III studies for pancreatic, prostate, and lung cancers and prior Phase Ib/II work in high-grade glioma, and CAN-3110 in Phase I for recurrent glioblastoma.

Valuation — source: SEC EDGAR (first-party)
Price	$8.33
Market Cap	$608.14M
P/E Ratio	-8.1
EV / EBITDA	-7.0
Price / Book	4.24
DCF Value (model)	$-7.40
DCF Upside vs Price	-188.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.08M
Net Margin	-1823.1%
Return on Equity	-39.4%
Debt / Equity	0.01
Current Ratio	28.05

Valuation vs Sector & Industry
Stock P/E	-8.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-138.6%
vs Industry	-147.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($53.84M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Paul-Peter Tak
Employees	38
Country	US
IPO Date	2021-07-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.